Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a sell rating to a hold rating in a research note released on Wednesday.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Down 4.8 %

ORMP stock opened at $2.37 on Wednesday. Oramed Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $3.67. The stock has a market capitalization of $95.54 million, a price-to-earnings ratio of 21.55 and a beta of 1.70. The firm’s fifty day simple moving average is $2.38 and its two-hundred day simple moving average is $2.39.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. XTX Topco Ltd lifted its position in shares of Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares during the last quarter. Murchinson Ltd. increased its stake in Oramed Pharmaceuticals by 0.5% in the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after buying an additional 8,889 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Oramed Pharmaceuticals during the 3rd quarter valued at about $272,000. BML Capital Management LLC boosted its position in Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after buying an additional 837,153 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the period. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.